India, June 17 -- Lifecore Biomedical, Inc. (LFCR) has entered a 10-year commercial manufacturing and supply agreement with an existing partner to advance a new ophthalmic treatment through clinical stages to market readiness.
The deal reflects Lifecore's broader growth strategy focused on late-stage customer projects approaching commercialization.
CEO Paul Josephs emphasized that this long-term agreement marks a key milestone in transitioning from development to revenue-generating commercial manufacturing. In parallel, Lifecore signed a multi-million-dollar statement of work to deliver a series of fill and finish CDMO services. This includes producing various batches of the drug candidate, including Process Performance Qualification - PP...